| FAFGX | MSGUX | FAFGX / MSGUX | |
| Total Expense Ratio | 0.40 | 1.62 | 25% |
| Annual Report Gross Expense Ratio | 0.40 | 1.62 | 25% |
| Fund Existence | 5 years | 11 years | - |
| Gain YTD | 20.388 | 25.803 | 79% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 1000 | 25% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 339B | 4.19B | 8,100% |
| Annual Yield % from dividends | 0.49 | 0.00 | - |
| Returns for 1 year | 8.19 | 20.15 | 41% |
| Returns for 3 years | 65.28 | 98.50 | 66% |
| Returns for 5 years | 34.63 | -37.81 | -92% |
| Returns for 10 years | N/A | 27.10 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| NSCCX | 40.91 | 0.62 | +1.54% |
| Nuveen Small-Cap Value Opps C | |||
| BMSRX | 15.10 | 0.13 | +0.87% |
| MFS Blended Research Mid Cap Eq R1 | |||
| BCSAX | 10.23 | 0.08 | +0.79% |
| BlackRock Commodity Strategies Inv A | |||
| NBRRX | 28.70 | 0.19 | +0.67% |
| Neuberger Berman M/C Intrinsic Val R3 | |||
| JDEAX | 49.44 | 0.13 | +0.26% |
| JPMorgan US Research Enhanced Equity A | |||